title: Expression and clinicopathological significance of FSIP1 in breast cancer.
abstract: OBJECTIVE
  To investigate the clinicopathological significance of the expression of fibrous sheath interacting protein 1 (FSIP1) in breast cancer, serum samples, and wound fluid from patients with breast cancer.
  
  
  METHODS
  Wound fluid and serum samples from female patients with primary breast cancer, recurrent and metastatic breast cancer, and benign tumors were analyzed for FSIP1 expression using ELISA. 286 paraffin-embedded surgical specimens from breast cancer patients with at least 5 years of follow-up were included for FSIP1 expression assay using immunohistochemistry.
  
  
  RESULTS
  Expression of FSIP1 protein was significantly higher in breast cancer tissues compared to tumor-adjacent tissues (p = 0.001). Strong correlation was observed between FSIP1 expression and human epidermal growth factor receptor 2 (Her-2) or Ki67 expression in breast cancer (p = 0.027 and 0.002, respectively). Similarly, serum level of FSIP1 was higher in patients with recurrent and metastatic breast cancer compared to that of primary breast cancer (7, 713 ± 3, 065 vs. 4, 713 ± 3, 065 pg/ml, p = 0.003). Finally, patients with high FSIP1 expression showed a worse post-operative disease-specific survival (p = 0.024).
  
  
  CONCLUSIONS
  FSIP1 may play an important role in the tumorigenesis and invasion of breast cancer and is a potential biomarker for breast cancer diagnosis or prognosis.
authors.affiliation: Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, China.
authors.forename: Hao
authors.initials: H
authors.lastname: Zhang
authors.affiliation: Department of Oncology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
authors.forename: Minna
authors.initials: M
authors.lastname: Luo
authors.affiliation: Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, China.
authors.forename: Zining
authors.initials: Z
authors.lastname: Jin
authors.affiliation: Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Wang
authors.affiliation: Shengjing Hospital, China Medical University, Shenyang, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Sun
authors.affiliation: Department of Oncology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
authors.forename: Xinhan
authors.initials: X
authors.lastname: Zhao
authors.affiliation: Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, China.
authors.forename: Zuowei
authors.initials: Z
authors.lastname: Zhao
authors.affiliation: Institute of Cancer Stem Cell, Cancer Center, Dalian Medical University, Dalian, China.
authors.forename: Haixin
authors.initials: H
authors.lastname: Lei
authors.affiliation: Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, China.
authors.forename: Man
authors.initials: M
authors.lastname: Li
authors.affiliation: Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Hospital of Dalian Medical University, Dalian, China.
authors.forename: Caigang
authors.initials: C
authors.lastname: Liu
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000097:blood / Q000378:metabolism* / Q000473:pathology*; D002352:Carrier Proteins / Q000096:biosynthesis* / Q000097:blood / Q000235:genetics; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D011379:Prognosis; D029589:Seminal Plasma Proteins / Q000096:biosynthesis* / Q000097:blood / Q000235:genetics
chemical_list: D002352:Carrier Proteins; C552592:FSIP1 protein, human; D029589:Seminal Plasma Proteins
keywords: FSIP1; breast cancer; metastasis; prognosis
references.citation: Jpn J Pharmacol. 2001 Nov;87(3):181-8
references.pmid: 11885966
references.citation: Ann N Y Acad Sci. 2002 Jun;968:37-48
references.pmid: 12119266
references.citation: Ann N Y Acad Sci. 2002 Jun;968:139-47
references.pmid: 12119273
references.citation: J Natl Cancer Inst. 2004 Jun 16;96(12):926-35
references.pmid: 15199112
references.citation: Endocr Rev. 1999 Jun;20(3):321-44
references.pmid: 10368774
references.citation: Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1339-44
references.pmid: 15677324
references.citation: Br J Haematol. 2008 Feb;140(4):465-8
references.pmid: 18217892
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7196-206
references.pmid: 19920112
references.citation: Cancer Sci. 2010 Mar;101(3):815-9
references.pmid: 20028381
references.citation: J Clin Oncol. 2010 Apr 1;28(10):1684-91
references.pmid: 20194857
references.citation: BMC Pulm Med. 2010;10:34
references.pmid: 20513247
references.citation: J Clin Oncol. 2010 Jul 10;28(20):3271-7
references.pmid: 20498394
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Prostate. 2012 Jan;72(1):12-23
references.pmid: 21520158
references.citation: Mol Cell Biol. 2012 Oct;32(20):4131-40
references.pmid: 22869527
references.citation: PLoS One. 2012;7(10):e46670
references.pmid: 23056395
references.citation: Biomark Med. 2013 Aug;7(4):601-11
references.pmid: 23905897
references.citation: Breast Cancer Res. 2014;16(4):408
references.pmid: 25056574